类风湿关节炎患者接受托法替布与TNF抑制剂治疗的扩展主要不良心血管事件终点风险:一项3b/4期随机安全性研究的的事后分析
ORAL Surveillance 3b/4期随机安全性研究的事后分析,纳入≥50岁且≥1个心血管危险因素的类风湿关节炎患者,比较托法替布5mg或10mg每日两次与TNF抑制剂对扩展MACE复合终点及组分事件的风险;
要点
- MACE-4至MACE-8复合终点风险在托法替布与TNF抑制剂之间相似。
- 合并动脉粥样硬化性心血管疾病或年龄≥65岁者,托法替布扩展MACE风险看似更高。
核心结论
- 在ORAL Surveillance中,托法替布与TNF抑制剂相比,合并所有缺血性心血管事件和心力衰竭的复合心血管终点风险未见差异。
- 托法替布10mg每日两次的总体心血管风险高于TNF抑制剂,由静脉血栓栓塞增加驱动。
研究设计与样本
- ORAL Surveillance(NCT02092467)的事后分析,纳入年龄≥50岁且至少1个额外心血管危险因素的类风湿关节炎患者。
- 患者接受托法替布5mg或10mg每日两次或TNF抑制剂治疗。
- MACE-3为非致死性心肌梗死、非致死性卒中或心血管死亡;依次增加心血管事件定义MACE-4至MACE-7(因不稳定型心绞痛住院、冠状动脉血运重建、短暂性脑缺血发作、外周血管疾病),增加心力衰竭住院定义MACE-8,MACE-8加VTE为MACE-8联合静脉血栓栓塞。
- 评估托法替布与TNF抑制剂的风险比(HR),涵盖MACE及各组分事件。
主要发现
- 托法替布合并剂量及单剂量与TNF抑制剂相比,MACE-4至MACE-8的HR相似。
- 托法替布与TNF抑制剂相比心肌梗死风险更高,但其他个体心血管事件风险差异未被提示。
- 在扩展MACE定义下,合并动脉粥样硬化性心血管疾病或年龄≥65岁的患者中,托法替布与TNF抑制剂相比风险看似更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance. METHODS: Patients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. MACE (non-fatal myocardial infarction (MI), non-fatal stroke or CV death (MACE-3)) was extended by sequential addition of CV events (hospitalisation for unstable angina (MACE-4), coronary revascularisation (MACE-5), transient ischaemic attack (MACE-6), peripheral vascular disease (MACE-7)), heart failure (HF) hospitalisation (MACE-8) and venous thromboembolism (VTE; (MACE-8 plus VTE)). HRs (tofacitinib vs TNFi) were evaluated for MACE and individual components. RESULTS: HRs for MACE-4 to MACE-8 with combined and individual tofacitinib doses versus TNFi were similar. Risk of MACE-8 plus VTE appeared similar with tofacitinib 5 mg two times per day versus TNFi (HR 1.12 (0.82 to 1.52)), but higher with tofacitinib 10 mg two times per day versus TNFi (HR 1.38 (1.02 to 1.85)). Risk of MI was higher with tofacitinib versus TNFi, but difference in risk of other individual CV events was not suggested. Across extended MACE definitions, risk appeared higher with tofacitinib versus TNFi in those with atherosclerotic CV disease or age ≥65 years. CONCLUSION: In ORAL Surveillance, risk of composite CV endpoints combining all ischaemic CV events and HF did not appear different with tofacitinib versus TNFi. The totality of CV risk was higher with tofacitinib 10 mg two times per day versus TNFi, driven by an increase in VTE. TRIAL REGISTRATION NUMBER: NCT02092467.
引用
- Buch MH, Bhatt DL, Charles-Schoeman C, et al. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 2024. PMID: 38609322. doi:10.1136/rmdopen-2023-003912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。